Table 2 Comparison of baseline characteristics between groups 1 and 2

Patients

76

21

55

 Ages (years)

39.2 ± 5.8 (22.0–53.0)

40.3 ± 6.0 (29.0–53.0)

38.8 ± 5.9 (22.0–50.0)

0.331

 Body mass index (kg/m2)

19.8 ± 1.8 (17.2–25.4)

20.4 ± 2.1 (17.8–25.4)

19.6 ± 1.6 (17.2–24.2)

0.072

 Subcutaneous fat thickness (mm)

11.6 ± 4.8 (3.0–26.0)

14.3 ± 5.8 (3.0–26.0)

10.6 ± 3.9 (3.0–20.0)

0.002*

 Baseline symptom severity score^a

52.4 ± 16.1 (21.9–93.8)

51.9 ± 16.2 (21.9–87.5)

52.6 ± 16.3 (21.9–93.8)

0.871

  Bulk effect

67

20

47

0.430

  AUB

39

10

29

0.799

0.003*

  Anteverted

48

19

29

  Retroverted

28

2

26

Number of fibroid treated (total)

2.8 ± 3.1 (1–15)

2.6 ± 3.0 (1–12)

2.8 ± 3.1 (1–15)

0.805

  1fibroid

45

14

31

  2–5 fibroids

18

4

14

  6–9 fibroids

8

2

6

  ≥ 10 fibroids

5

1

4

 Diameter (cm)^b

6.6 ± 2.6 (2.1–15.1)

6.2 ± 2.7 (2.6–15.0)

6.7 ± 2.6 (2.1–15.1)

0.494

 Volume (ml)^b

157.3 ± 141.3 (6.0–794.0)

156.7 ± 164.7 (37.0–7.094)

157.5 ± 133.0 (6.0–637.0)

0.983

 Distance (mm)^c

92.4 ± 17.0 (57.0–133.0)

90.7 ± 13.0 (57.0–117.0)

93.1 ± 18.3 (63.0–1.033)

0.581

 Bowel Displacement Technique^d

0.536

  Yes

58

15

43

  No

18

6

12

 Location

0.669

  Intramural

38

9

29

  Subserosal

21

6

15

  Submucosal

17

6

11